Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03293498 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)
A Phase 1 study, sponsored by Novavax.
- Completed
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
NCT03293498 is a Phase 1 study that has completed, run by Novavax. The registered enrollment target is 330 participants.
The verdict
NCT03293498, a Phase 1 study, has completed, sponsored by Novavax.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
Study Summary
This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older Adults ≥ 60 Years of Age
Interventions
- BIOLOGICAL NanoFlu
- BIOLOGICAL Fluzone HD - Day 0
- BIOLOGICAL Fluzone HD - Day 21
- OTHER Saline - Day 21
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2017-09-18 |
| Est. Completion | 2018-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03293498
The ClinicalTrials.gov registry entry for NCT03293498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novavax, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which NanoFlu is the first listed.
NCT03293498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03293498 about?
NCT03293498 is a clinical study titled "Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)". This was a Phase 1/2, randomized, observer-blinded, active-controlled trial to assess the Safety and Tolerability of a Recombinant Trivalent Nanoparticle Influenza Vaccine (Tri-NIV) with Matrix M1™ Adjuvant in Healthy Older Adults ≥ 60 Years of Age
What is the current status of trial NCT03293498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2017-09-18. Estimated completion is 2018-10-29.
What interventions are being tested in trial NCT03293498?
The interventions under investigation include: NanoFlu (BIOLOGICAL), Fluzone HD - Day 0 (BIOLOGICAL), Fluzone HD - Day 21 (BIOLOGICAL), Saline - Day 21 (OTHER).
Who is sponsoring clinical trial NCT03293498?
This trial is sponsored by Novavax, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.